BeOne Medicines (BEIGF) Operating Income (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Operating Income data on file, last reported at $249.9 million in Q1 2026.

• Operating Income for Q1 2026 came in at $249.9 million, up 2150.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $685.9 million (up 331.93% YoY), and the FY2025 annual result was $447.1 million, up 178.69% from the prior year.
• Operating Income rose to $249.9 million in Q1 2026 per BEIGF's latest filing, from $185.0 million in the prior quarter.
• Over five years, Operating Income peaked at $249.9 million in Q1 2026 and troughed at -$468.6 million in Q4 2022.
• A 5-year average of -$168.7 million and a median of -$134.0 million in 2023 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2026: Operating Income tumbled 731.76% in 2022, then soared 2150.96% in 2026.
• A 5-year view of Operating Income shows it stood at -$468.6 million in 2022, then gained by 18.1% to -$383.8 million in 2023, then soared by 79.31% to -$79.4 million in 2024, then soared by 332.97% to $185.0 million in 2025, then surged by 35.06% to $249.9 million in 2026.
• Business Quant data shows BEIGF's Operating Income at $249.9 million in Q1 2026, $185.0 million in Q4 2025, and $163.1 million in Q3 2025.